In contrast, our GWAS explored various genes (AK3, TRPM3, CDH4, LINC00504, GRIN2D, HPGD, RC3H2, PCSK6, NPAS3, and DMXL2), which had significantly variable impacts on clinical outcomes of DOX after TACE in HCC patients. The gene discussed is CDH4; the disease is hepatocellular carcinoma.